Regulating Synthetic Biology and Gene Editing Technologies- Balancing Innovation, Ethics, and Legal Governance

Author: Gunda Dinesh, Alliance University

---

Abstract

Synthetic Biology and Gene editing, particularly CRISPR-Cas9 technology is a ground breaking discovery in biotechnology, enabling accurate modifications of genetic material for applications in medicine, agriculture, healthcare and environmental conservation. This paper focuses on the evolving legal frameworks regulating these technologies, with a focus on balancing innovation with ethical imperatives such as safety, equity, consent and ecological risks. This paper conducts a doctrinal and comparative analysis of international instruments such as the Cartagena Protocol on Biosafety, US (FDA Coordinated Framework), EU and other national legislations, as well as ethical issues raised by such landmark cases as "CRISPR babies" in 2018. The primary findings indicate that harmonised, risk-based worldwide rules are necessary to encourage responsible innovation and prevent negative outcomes. It highlights regulatory deficiencies including germline editing and dual-use risks and explores adaptive regulatory approaches. The paper provides certain policy implications regarding responsible governance of synthetic biology.

Keywords: Synthetic Biology, Gene Editing, CRISPR-Cas9, Biosafety, Bioethics, Cartagena Protocol, Germ-line Editing, Regulatory Governance.

Introduction

The advancements in synthetic biology and gene editing technology have created a new age of biological engineering which has the potential to solve some of the world’s problems in relation to genetic disease, food scarcity, and climate change. CRISPR-Cas9, an innovative gene-editing technology based on a natural process utilized by bacteria for protection, is now making it possible for scientists to edit genes with great efficiency, accuracy, and cost-effectiveness, unlike the previous methods, such as Zinc Finger Nucleases (ZFNs) and Transcription Activator-Like Effector Nucleases (TALENs), the CRISPR-Cas9 method proves to be more precise, cost-effective, and simple to perform. It allowed scientists to fix genetic defects causing various hereditary illnesses, increase the pest and climatic resistance of crops, design personalized drugs, and make advances in synthetic biology. But this technology has created significant concerns in terms of its legal and ethical implications: 

 (a)Who will decide what genetic changes are acceptable?

 (b) How can unwanted outcomes be avoided?

 The 2018 declaration by Chinese researcher He Jiankui about using gene editing in creating “CRISPR babies” Lulu and Nana explained such issues.

Various international regulations have been developed to control the area of biotechnology. These include the Convention on Biological Diversity (CBD), the Cartagena Protocol on Biosafety, the Nagoya Protocol on Access and Benefit Sharing, the UNESCO Universal Declaration on the Human Genome and Human Rights, and the International Health Regulations. However, despite these regulations, they mainly deal with genetically modified organisms and issues concerning biodiversity conservation rather than new developments like synthetic biology and gene editing techniques.

The rapid rate of scientific progress has therefore outstripped the growth of legal institutions. When it comes to solving new scientific hazards that grow across national borders, traditional regulatory methods frequently fall short and a need for new regulations arise immediately. Furthermore, a multidisciplinary regulatory approach that combines legal principles with scientific knowledge and ethical reasoning is required to address ethical issues pertaining to germline modification, human enhancement, genetic discrimination, patentability of biological inventions, and intergenerational justice.

The effectiveness of current legal frameworks in striking a balance between innovation and ethics is the main study question. The following are among the objectives: 

(1) Mapping important national and international rules.

(2) Examining doctrinal, comparative, and ethical aspects. 

(3) Finding gaps.

(4) Suggesting revisions. Using statutes, cases, academic literature, and regulatory reports as sources, this paper employs a doctrinal and comparative approach.

Literature Review

The existing literature focuses on regulatory governance, ethics, intellectual property, biosafety, and human rights issues. There are many existing studies on an international level, but comparatively lesser ones provide a comprehensive study of the laws regarding synthetic biology and gene editing technologies in India.

One of the earliest works done in this field is by Sheila Jasanoff, which states that the process of scientific regulation cannot be done only through scientific knowledge, but it has to include aspects like democracy, public involvement, and ethics. According to Jasanoff, biotechnology regulation involves more than just scientific regulation, it is a constitutional issue and human rights issue since it includes the data. The international literature is based mainly on the Convention on Biological Diversity (CBD) and the Cartagena Protocol on Biosafety (2000). The latter regulates living modified organisms (LMOs) generated through biotechnology. There are discussions regarding whether organisms produced by genome editing should be considered LMOs since some researchers believe that SDN-1 edits replicate natural mechanisms and thus fall out of the regulation sphere.

Jennifer Doudna and Samuel Sternberg provided a detailed scientific description of the CRISPR-Cas9 technology while also addressing its deep legal and ethical consequences. The two authors state that although gene editing holds unparalleled medical benefits, the technology poses risks concerning designer babies, germline editing, consent, and the possibility of creating irreversible changes to human genes that will affect future generations. 

The role of international law in the governance of genetically modified organisms has been thoroughly studied from the perspective of the Convention on Biological Diversity and the Cartagena Protocol on Biosafety. Nonetheless, some experts such as Tade Matthias Spranger suggest that these documents were created long before the development of synthetic biology, which is why they cannot be used effectively to solve modern issues linked to artificial genome and synthetic organisms.

Ethical aspects of genetic modification have been analyzed by Julian Savulescu, He believes that genome editing should be cautiously accepted in medicine but not unregulated human enhancement. According to Savulescu, ethical regulation of gene editing ought to make a clear distinction between disease prevention and enhancement, stressing the importance of beneficence, autonomy, and justice. At the same time, opponents of gene editing, like Marcy Darnovsky, warn that commercialization of the technology may contribute to increased inequality and provide people with genetic benefits only if they are well-off financially.

Intellectual property experts have concentrated on highly controversial CRISPR patent lawsuits between the University of California and the Broad Institute. Patent issues of CRISPR technology have raised broader questions about intellectual property rights of foundational genetics technology, monopoly patents, access to medical breakthroughs, and incentives to innovations. Intellectual property experts acknowledge that excessive patent protection may negatively affect cooperation in science and insufficient protection will discourage private investments in innovations.

The literature on Indian law has provided more attention to the biosafety regulation and genetically modified plants instead of synthetic biology. The publications of the Indian Council of Medical Research and the Department of Biotechnology have highlighted the importance of ethics review, institutional biosafety committee, and clinical research governance. However, A number of reports developed by the World Health Organization have proposed setting up global governance structures for human genome editing with a focus on transparency, international collaboration, scientific responsibility, and public engagement. In the same way, the declarations of UNESCO regarding human genome have stressed the necessity to protect human dignity and promote scientific research responsibly.

Therefore, this research aims to fill these gaps through a comprehensive legal analysis of the field of synthetic biology and gene editing. The research will compare the international laws along with the Indian law on this issue while making suggestions for reforms that can maintain the balance between scientific advancement and ethics.

Methodology

This research uses the doctrinal and comparative legal research methodology for exploring the legal framework of synthetic biology and gene editing technologies. This research methodology is chosen as it suits the nature of the research where the focus is on the analysis of legal principles, statutory provisions, case laws, international conventions, guidelines, and literature on biotechnology law. The aim is to analyze if the existing legal systems are enough to deal with the scientific, ethical, and societal concerns emanating from developments in the field of synthetic biology and genome editing.

The doctrinal aspect of the research will include an intensive analysis of the domestic legislation, such as the Environment (Protection) Act, 1986, Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms, Genetically Engineered Organisms or Cells, 1989, DBT guidelines, and ICMR guidelines, in relation to constitutional principles on the right to life, public health, environment, scientific research, and human dignity. The use of the doctrinal method is well-suited for analyzing Bluebook sources such as the Cartagena Protocol and the FDA guidance documents. Comparative components include assessing how product-oriented and process-oriented systems deal with innovation and risks, respectively.

Secondary sources play a vital role in this research. Academic articles, books, governmental reports, policy papers, international organizations' reports, and peer-reviewed scientific journals have been thoroughly reviewed to identify ongoing discussions related to biosafety, bioethics, intellectual property, human rights, and biotechnology governance. Special attention has been paid to identifying regulatory gaps with regard to synthetic biology and sophisticated gene-editing technologies, including CRISPR-Cas9, base editing, and prime editing.

The research is of qualitative nature and will not be conducted through the use of empirical surveys and interviews. Rather, the purpose is to evaluate legal doctrines through reasoning and analysis of policy approaches. Such methodology has been chosen as it allows conducting a comprehensive study of the current regulation of biotechnology, as well as proposing legislative solutions to balance scientific innovations with ethics and environmental sustainability.

Synthetic Biology: Concept, Evolution and Scope

Synthetic biology stands as one of the most important breakthroughs in science in the twenty-first century. In contrast to conventional genetic engineering that normally consists of gene manipulation, synthetic biology employs biology, engineering, computing, chemistry, and mathematics for designing and creating new biological systems with a particular function. This area of science allows scientists to not only modify life but design biological parts for the fulfilment of certain goals and allows the scientists to build systems functioned to precise specifications.

The emergence of synthetic biology is because of the progress in molecular biology that took place in the last part of the twentieth century. The successful completion of the Human Genome Project, reduction in DNA sequencing costs, progress in computational biology, and automation of DNA synthesis made biotechnology into an engineering science. Artificial genetic circuits, synthetic microbes, programmable cells, and artificial biological pathways can now be designed by scientists.

The primary aim of synthetic biology is to engineer biological entities and study the activities of DNA,RNA and proteins closely in order to be applied practically. Applications of such engineering may involve the creation of medicines, fuels, degradable polymers, crop resistance to various diseases, carbon dioxide capture systems, environment restoration methods, vaccine development, and precision medicine. In the times of the COVID-19 pandemic, synthetic biology helped develop vaccines based on mRNA faster than ever before.

Synthetic biology has passed several phases in its evolution process. Initially, the science was aimed at researching biological processes as they occur in nature. After that came genetic engineering which enabled researchers to introduce some genes from other organisms into living ones. The current synthetic biology goes beyond gene introduction as it allows building artificial chromosomes, biological circuits, and minimal synthetic cells capable of performing highly specialized biological functions.

In spite of these impressive developments, the emergence of synthetic biology poses serious regulatory challenges. Artificial organisms can have features that may be markedly different from those of natural organisms, posing uncertainties about their safety for the environment, their interaction with ecosystems, liability in case of any unintended effects, and their evolution in the long run. Biosafety laws were mostly drafted for genetically modified organisms (GMOs) rather than for artificial organisms/synthetic organisms with new biological features.

There is no clear legal definition of synthetic biology at all at the moment. Although the Convention on Biological Diversity defines synthetic biology as one of the forms of modern biotechnology in general, national legal systems have different definitions, resulting in inconsistent regulation of this phenomenon. There are numerous uncertainties with respect to licensing issues, environmental risks, biosafety requirements, and the transport of synthetic organisms internationally. Therefore, the process of regulating should go beyond the framework of existing biotechnology law and include adaptive risk assessment procedures.

Gene Editing Technologies: Scientific Advancement and Legal Implications

Gene editing is a collection of molecular techniques used to precisely edit the DNA sequence within an organism. While genetic engineering involves addition of foreign genes within an organism, gene editing allows deletion, insertion, replacement or mutation of particular genetic sequence with high precision.

(a) Zinc Finger Nucleases (ZFNs)

One of the early genome editing methods was that of Zinc Finger Nucleases (ZFNs), which are artificially produced enzymes that consist of zinc finger proteins and nucleases that cut DNA at specified regions.

While this technique brought a significant step forward in genome editing, the production process was costly and complicated, thus limiting its use on a larger scale. As far as law is concerned, ZFNs started the discussion about patenting genome editing technologies and engineered biological tools.

(b) Transcription Activator-Like Effector Nucleases (TALENs)

TALEN technology brought further improvement to genome editing, enabling targeting of a longer DNA sequence with lower rates of off-target mutations. The technique found its use in agricultural biotechnology, biomedical research and treatment of hereditary diseases.

However, TALENs were rather costly and difficult to produce, making researchers look for alternatives to genome editing.

(c) CRISPR- Cas9

Development of CRISPR- Cas9 has significantly advanced biotechnology. Initially identified as a part of the defense mechanism of bacteria, CRISPR allows scientists to target specific DNA sequences and make changes to it with the help of guide RNA and Cas9 enzymes.

The benefits of CRISPR technology are:

• High level of precision.

• Relatively cheap cost.

• Quick results.

• Possibility of simultaneous modification of multiple genes.

• Wide range of applications in various species.

CRISPR technology has radically changed approaches to research of:

• Genetic diseases.

• Cancer.

• Rare diseases.

• Biotechnological agriculture.

• Synthetic biology.

• Xenotransplantation.

• Regenerative medicine.

However, CRISPR also raises serious legal and ethical issues. Human germline editing has the ability to cause irreversible genetic modifications, which will be passed to future generations. Germline modification is unlike somatic gene therapy, because its influence applies to children, who cannot give an informed consent to it. The issues of reproductive rights, human dignity, intergenerational justice and eugenics became the center of public debates. Creation of modified twins in China in 2018 showed all possible risks of unregulated use of genome editing techniques.

(d) Base Editing and Prime Editing

The latest advances in the field of science have provided even more sophisticated forms of gene editing. Base editing is the process of alteration of DNA base at a single location without producing any double-strand breaks and thus avoiding any unnecessary mutations. In prime editing, there is an additional advantage of making insertions, deletions, and substitutions of DNA bases with the least impact on the cell. While there is significant improvement in terms of therapeutic applications, it also complicates the regulatory framework due to the fact that the legislation does not consider sophisticated molecular modifications as genetic engineering.

International Legal Framework Governing Synthetic Biology and Gene Editing 

Due to the transnational nature of biotechnology research, international law has become indispensable for setting minimum standards related to biosafety, protection of the environment, ethics, and cooperation between nations.

1. Convention on Biological Diversity (CBD), 1992

The Convention on Biological Diversity (CBD) is an international treaty that regulates conservation of biological diversity, sustainable use of biological resources, and equitable sharing of benefits derived from genetic resources. While the treaty was developed before the rise of synthetic biology, Conferences of Parties have since come to recognize the importance of synthetic biology in terms of regulatory control. But the Convention does not address regulations of genome-editing techniques like CRISPR.

2. Cartagena Protocol on Biosafety, 2000

Cartagena Protocol is an additional protocol to CBD which deals with transboundary movement of Living Modified Organisms (LMOs).Its main objectives include: environmental risk assessment, prior informed consent procedure, biosafety information exchange, and public awareness. The Cartagena Protocol reflects the principle of precaution, allowing states to impose restrictions on genetically modified organisms when there is scientific uncertainty about environmental risks. However, whether organisms edited by means of CRISPR are considered living modified organisms is disputable.

3. Nagoya Protocol, 2010

Nagoya Protocol outlines international regulations on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization.

Synthetic biology makes it difficult to implement such provisions since synthetic DNA replicates natural genetic material without having physical access to biological material, making it difficult to establish who owns the information about such genetic material and how benefits would be shared.

4. UNESCO Universal Declaration on the Human Genome and Human Rights (1997)

UNESCO identifies human genome as the common heritage of mankind and stresses that attention needs to be paid to protection of:

• Human dignity.

• Equality.

• Non-discrimination.

• Informed consent.

• Privacy.

Though not legally binding, the Declaration has a strong influence on ethical governance of genome editing.

5. WHO Recommendations

The World Health Organization has been stressing the importance of international governance with scientific evaluation, ethical oversight, and public engagement of human germline editing.

WHO further recommends:

• International genome editing registries.

• Independent ethics committees.

• More governmental regulation.

• Global scientific cooperation.

These recommendations aim at preventing any kind of unethical experiments while allowing biomedical research to go on.

Indian Legal Framework Governing Synthetic Biology and Gene Editing

India has emerged to be among the fastest growing biotech destinations in the world due to major developments in such fields as pharmaceutics, genomics, Agri genomics, vaccination, and precision medicine. Nonetheless, the fast-paced scientific developments do not go hand-in-hand with a specialized legal framework dealing with synthetic biology and gene editing. The existing system of biotechnology regulation comprises a range of different laws, executive regulations, policies and regulatory agencies.

The lack of a unified biotechnology regulation system in India has resulted in uncertainties in respect of licensing, ethical approval, liability requirements, clinical use and commercialization of new genetic technologies. As a result, legal experts have put forward proposals for a special Biotechnology Regulation Act. The regulatory authorities include:

1. Environment (Protection) Act, 1986

2. Rules, 1989 (Hazardous Microorganisms, Genetically Engineered Organisms or Cells)

3. Genetic Engineering Appraisal Committee (GEAC)

4. Department of Biotechnology (DBT)

5. Indian Council of Medical Research (ICMR)

6. Institutional Biosafety Committees (IBSCs)

Even with the presence of multiple regulating agencies, there are several structural problems in the biotechnology governance of India. Including among others, lack of specialized legislation on synthetic biology, institutional jurisdictional overlap, inconsistencies in definition, gene editing technologies are inadequately regulated, lack of liability provisions, ambiguity in intellectual property laws, lack of participation by the public, inadequate ethical oversight for new technology. Thus, the Indian country needs to enact a comprehensive Biotechnology Governance Act.

Ethical Challenges in Synthetic Biology and Gene Editing

Lawful control of biotechnology cannot be separated from ethics. Scientific actions can be possible from a technical aspect but ethically wrong.

Genome editing poses numerous ethical issues that require proper legal deliberation.

(a) Human Germline Editing

Human germline editing entails altering the genes in reproductive cells or embryos with subsequent genetic changes passed down the line. Despite its great capacity to eradicate genetic disorders, there are numerous ethical problems associated with human germline editing including non-consent from future generations, permanent genetic effects, unknown risks, and the protection of human dignity. Most states have banned human germline editing due to its ethical and safety issues.

(b) Designer Babies

Editing genes could make it possible to design babies based on the desired attributes such as high intelligence, good looks, athleticism, and immunity to diseases. There are no issues with the therapeutic applications of gene editing. However, its use to enhance traits creates a number of ethical questions including social stratification, commercialization of human procreation, neo-eugenics, and the commodification of humans.

(c) Genetic Privacy

The process of genome sequencing involves obtaining highly sensitive genetic data that concerns the health, lineage, and biological relationship of the individual. Unauthorized acquisition and release of such data could lead to discriminatory practices by the employer, insurer, or any other body. Hence, there must be adequate legal measures put in place to ensure the security of genetic data.

(d) Genetic Discrimination

Discriminatory treatment of an individual based on his genetic make-up or potential vulnerability to diseases is referred to as genetic discrimination. It is illegal in many nations due to the presence of legal provisions to that effect. In India, however, there is no legislation covering this area.

Comparative Legal Analysis: International Approaches to Regulating Synthetic Biology and Gene Editing

The regulation of synthetic biology and gene editing technologies varies significantly from one jurisdiction to another. While some countries have adopted precautionary measures and regulations that focus on biosafety and ethics, others have created innovation-based regulatory regimes to encourage scientific development. Comparative analysis will enable the identification of some best practices that can be considered in the future reforms in India.

(a) European Union

One of the most developed biotech regulatory regimes in place is that of the European Union (EU). The regime is based on the Precautionary Principle, whereby regulatory agencies are required to assess any risk prior to approval for research or commercial purposes.

Legal instruments regulating biotech in the EU include:

Directive 2001/18/EC on the Deliberate Release of Genetically Modified Organisms.

Regulation (EC) No. 1829/2003 on Genetically Modified Food and Feed.

Regulation (EC) No. 1830/2003 on Traceability and Labelling.

In the decision of Case C-528/16, Confédération Paysanne v. Premier Ministre (2018), the Court of Justice of the European Union ruled that organisms produced through modern mutagenesis techniques, including some forms of genome editing, were regulated under GMO legislation, unless exempted.

(b) United States

The United States adopts the product based regulatory system as opposed to the European Union which regulates biotechnology on the basis of the production process alone.

Regulatory control is exercised by three main regulatory agencies:

1. Food and Drug Administration (FDA)

Charges with human gene therapy, biological products, medical devices, clinical trials.

2. United States Department of Agriculture (USDA)

Responsible for genetically engineered agricultural products and plants.

3. Environmental Protection Agency (EPA)

In charge of pesticides, microbial products and environmental biosafety.

The United States fosters biotechnology innovation through the relatively flexible regulatory control but continues to regulate the products that pose a real threat to safety. There is no explicit ban on human germline manipulation but its clinical application is effectively prevented due to funding and regulatory barriers.

Comparative Evaluation

The comparative analysis reveals two distinct regulatory measures. The European Union prioritizes precaution and environmental protection. The United States emphasizes scientific innovation and commercial development. India presently occupies an intermediate position but requires legislative modernization to effectively govern emerging biotechnology

Future Indian legislation should integrate:

• Adaptive regulation.

• Risk-based approval.

• Ethical review.

• Public participation.

• International cooperation.

Discussion

Regulation of synthetic biology and gene editing techniques stands among one of the biggest legal issues faced by modern regulatory institutions. Scientific progress is moving much faster than legislation, thus, regulatory uncertainties are found in a lot of jurisdictions.

Analysis has shown that international laws, such as Convention on Biological Diversity, Cartagena Protocol, declarations made by UNESCO, and recommendations from WHO, give significant ethical directions but do not contain enough regulations to control present technological advances like CRISPR, synthetic genomes, and programmable biology. International agreements had been created before these scientific achievements became technologically possible and thus need modernization.

India's regulatory system faces special difficulties. While different governmental organizations regulate activities related to biotechnological innovations, the present system is rather inconsistent and was developed for traditional genetic modification rather than genome editing. Lack of the proper legislation causes uncertainty concerning licensing, liability, intellectual property, application in medicine, and environmental issues. This research study proves again that ethical governance is not a barrier to scientific advancement. On the contrary, effective ethical regulation increases public trust and legitimacy of biotechnology research.

Recommendations:

• Enact a Comprehensive Biotechnology Regulation Act

• Establish an Independent National Biotechnology Authority

• Adopt Risk-Based Regulation

• Strengthen Bioethics Oversight

• Introduce Genetic Privacy Legislation

• Promote International Cooperation

• Encourage Responsible Innovation

Conclusion 

The growth of synthetic biology and gene-editing techniques has completely revolutionized biotechnology in modern times by providing unmatched precision in manipulation of genetic material. The uses of these techniques can be found in areas ranging from medicine and agriculture to environmental conservation, pharmaceuticals, industrial biotechnology, and scientific research. They hold a lot of promise for improving human well-being in the form of treating genetic disorders, increasing food security, developing sustainable industries, and addressing environmental issues.

However, rapid developments in technology have also raised serious legal and ethical questions. The existing regulatory systems, whether international or Indian, have been unable to keep up with the speed of scientific innovation. Issues related to germline editing of humans, designer babies, genetic discrimination, intellectual property, biosafety, environmental protection, and biosecurity are not comprehensively addressed under the existing laws.

The comparative study shows that different countries like the European Union, the United States, follow diverse regulatory approaches, which reflect their different balances between innovation and precaution. Despite being scientifically advanced, India still uses an ad hoc regulation system which is mostly for previous genetic engineering technologies.

This research paper study suggests that any future regulation of biotechnological practices must evolve from a purely reactionary approach to an adaptive and science-driven legal framework that is also guided by principles of ethics. These frameworks ought to harmonize various aspects of law, including environmental law, constitutional principles, medical ethics, international law, and principles of intellectual property rights.

However, at its heart, the goal of regulation of biotechnology ought not to be restricting innovations, it should simply aim at ensuring that innovations are carried out in accordance with basic principles of human dignity, justice, environmental sustainability, and the rule of law and with ethical concerns. It is possible for India to adopt such an innovative regulatory regime through comprehensive legislation and proper enforcement of rights.

References

• Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, 1869 U.N.T.S. 299.

• Cartagena Protocol on Biosafety to the Convention on Biological Diversity, Jan. 29, 2000, 2226 U.N.T.S. 208.

• Convention on Biological Diversity, June 5, 1992, 1760 U.N.T.S. 79.

• Department of Biotechnology, Government of India, Genome Editing Guidelines (2022), https://dbtindia.gov.in/regulations-guidelines.

• Food & Drug Administration, U.S. Department of Health & Human Services, Human Gene Therapy Products, https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products (last visited July 13, 2026).

• Genetic Technology (Precision Breeding) Act 2023 (U.K.).

• Indian Council of Medical Research, National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017), https://ethics.ncdirindia.org/ICMR_Ethical_Guidelines.aspx.

• Jennifer Doudna & Samuel Sternberg, A Crack in Creation (2017).

• Julian Savulescu, Genetic Enhancement and Human Nature, 35 Bioethics 321 (2021).

• Marcy Darnovsky, Biopolitics of Human Genome Editing, 30 Hastings Center Report 24 (2020).

• Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from Their Utilization to the Convention on Biological Diversity, Oct. 29, 2010, U.N. Doc. UNEP/CBD/COP/DEC/X/1.

• Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms, Genetically Engineered Organisms or Cells, 1989, G.S.R. 1037(E) (India).

• Sheila Jasanoff, Designs on Nature (Princeton University Press 2005).

• UNESCO Universal Declaration on the Human Genome and Human Rights (1997).

• U.S. Food & Drug Administration, Human Gene Therapy Products Incorporating Human Genome Editing: Guidance for Industry (Jan. 2024), https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-products-incorporating-human-genome-edi.

• World Health Organization, Human Genome Editing: Recommendations (2021), https://www.who.int/publications/i/item/9789240030381.